Holen Sie sich die Stockscreener-App
0.712
1.11%
-0.008
Handel nachbörslich:
.75
0.038
+5.34%
Reviva Pharmaceuticals Holdings Inc Aktie (RVPH) Neueste Nachrichten
Energy Moves: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant impacted by rising rates2026 Performance Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Volume Summary: Will Reviva Pharmaceuticals Holdings Inc Equity Warrant outperform during market rallies2026 Technicals & Expert-Curated Trade Recommendations - baoquankhu1.vn
Aug Analyst Calls: Is now the right time to enter Reviva Pharmaceuticals Holdings Inc2026 Macro Impact & Weekly Return Optimization Plans - baoquankhu1.vn
Form S-3Registration statement under Securities Act of 1933 - ADVFN
RVPH Should I Buy - Intellectia AI
Reviva Pharmaceuticals Holdings, Inc. (RVPHW) Fundamental Analysis - Meyka
RVPH|Reviva Pharmaceuticals Holdings Inc|Price:0.720|Chg%:-0.09 - tradingkey.com
Roth MKM Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Roth MKM Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Cuts Target Price to $1 - Moomoo
Aug Wrap: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant in a bullish channel2026 Final Week & High Conviction Investment Ideas - baoquankhu1.vn
Portfolio Recap: Is now the right time to enter Reviva Pharmaceuticals Holdings Inc2026 Price Targets & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Reviva Pharmaceuticals advances schizophrenia drug with new trial plans - Intellectia AI
Market Wrap: How do insiders feel about Reviva Pharmaceuticals Holdings Inc Equity WarrantDollar Strength & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Integrated/Millennium group reports 6.2% stake in Reviva (RVPH) via 13G - Stock Titan
Reviva Pharmaceuticals Reports 2025 Financial Results and Corporate Updates, Including Brilaroxazine Progress and Patent Portfolio Expansion - Minichart
Reviva Pharmaceuticals 2025 Financial Review - AlphaStreet
Reviva Pharmaceuticals Advances Brilaroxazine for Schizophrenia: Clinical Trial Results, Pipeline, and Future Outlook - Minichart
Reviva Reports Positive 2025 Results, Plans Next Phase 3 Trial for Schizophrenia Drug - National Today
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights - The Manila Times
Reviva Pharmaceuticals Holdings 2025 10-K: Net Loss $0.20/share; Cash $14.44M - TradingView
RVPH: Net loss narrowed in 2025 as brilaroxazine advanced toward a pivotal Phase 3 trial and regulatory milestones - TradingView
Reviva (RVPH) trims 2025 loss as it readies RECOVER-2 Phase 3 for brilaroxazine - Stock Titan
RVPH: Net loss improved to $19.9M in 2025; cash sufficient into early 2027, but more funding required - TradingView
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Published on: 2026-03-30 09:13:20 - baoquankhu1.vn
Reviva Pharmaceuticals Holdings (RVPH) price target increased by 2,046.68% to 117.30 - MSN
Top 10 stocks under $5 that could triple - MSN
Reviva Pharmaceuticals Holdings, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Analysts remain confident in Reviva Pharmaceuticals Holdings (RVPH) amid 1-for-20 reverse stock split - MSN
Targets Report: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant stock showing strong momentumChart Signals & Safe Swing Trade Setups - baoquankhu1.vn
Growth Recap: Will Reviva Pharmaceuticals Holdings Inc benefit from green energy policiesGDP Growth & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Reviva Pharmaceuticals Holdings Inc expected to post a loss of $1.17 a shareEarnings Preview - TradingView
Reviva Pharmaceuticals (NASDAQ: RVPH) posts strong brilaroxazine Phase 3 data but plans new pivotal trial - stocktitan.net
If You Invested $1,000 in Reviva Pharmaceutcls Hldgs Inc (RVPH) - Stock Titan
Quarterly Trades: How correlated is Reviva Pharmaceuticals Holdings Inc to the S P5002026 EndofMonth & Verified Short-Term Trading Plans - baoquankhu1.vn
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split - Insider Monkey
CVI/Heights disclose 666,667 shares (5.2%) in Reviva Pharmaceuticals (NASDAQ: RVPH) - Stock Titan
Aug Mood: Can Reviva Pharmaceuticals Holdings Inc Equity Warrant stock outperform in a bear marketWeekly Stock Analysis & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Parag Saxena reports Reviva (RVPH) stake at 2.8%, below 5% level - Stock Titan
Reviva Pharmaceuticals raises $10 million in public offering By Investing.com - Investing.com Canada
Reviva Pharmaceuticals raises $10 million in public offering - Investing.com
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering - The Manila Times
Reviva says $10M raise funds schizophrenia trial into Q1 2027 - Stock Titan
What's behind the drop in Reviva Pharmaceuticals stock? - MSN
Aug Levels: Can Reviva Pharmaceuticals Holdings Inc Equity Warrant benefit from deglobalization2026 Spike Watch & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Wall Street Recap: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant being accumulated by smart moneyM&A Rumor & High Win Rate Trade Alerts - baoquankhu1.vn
Reviva Pharmaceuticals Announces $10 Million Equity Offering - The Globe and Mail
Reviva (NASDAQ: RVPH) CFO granted 40,925 stock options under 2020 plan - Stock Titan
Reviva (RVPH) CEO receives 150,075 stock option grants under 2020 plan - Stock Titan
Reviva Pharmaceuticals Holdings Announces Securities Purchase Agreement and New Warrants Offering March 2026 - Minichart
Reviva Pharmaceuticals (NASDAQ: RVPH) raises equity with detachable warrants and pre‑funded options - Stock Titan
Reviva (NASDAQ: RVPH) prices $10M equity deal to fund Phase 3 trial - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
What's Behind The Drop In Reviva Pharmaceuticals Stock? - Benzinga
Dow Falls Over 300 Points; US Initial Jobless Claims Fall - Benzinga
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):